6 assets in Reticular Dysgenesis

Therapeutic assets addressing Reticular Dysgenesis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Reticular Dysgenesis	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Busulfanum Reticular Dysgenesis	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Cyclophosphamide Reticular Dysgenesis	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Fludarabine Reticular Dysgenesis	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Melphalan Reticular Dysgenesis	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna Reticular Dysgenesis	Masonic Cancer Center, University of Minnesota	N/A	D (30)